Navidea Biopharmaceuticals to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
September 08 2017 - 10:00AM
Business Wire
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) (“Navidea” or
“the Company”), a company focused on the development of precision
immunodiagnostic agents and immunotherapeutics, today announced it
will present at the Rodman & Renshaw 19th Annual Global
Investment Conference, being held September 10-12, 2017, in New
York, NY. Michael Goldberg, M.D., Chief Executive Officer of
Navidea, will be giving a presentation and meeting with investors
throughout the conference.
Event:
Rodman & Renshaw 19th Annual Global Investment
Conference
Date:
Tuesday, September 12, 2017
Time:
4:40pm ET
Location:
Lotte New York Palace, New York, NY
For investors attending the Rodman & Renshaw conference,
please contact Navidea Investor Relations to schedule a meeting
with Navidea management at tpatel@edisongroup.com or
ir@navidea.com.
If you are an institutional investor, and would like to attend
the Company’s presentation, please click on the following link
(www.rodmanevents.com) to register for the Rodman & Renshaw
conference. Once your registration is confirmed, you will be
prompted to log into the conference website to request a one-on-one
meeting with the Company.
The presentation will be webcast live and remain available for
90 days following the presentation. To access the webcast, please
visit the Events tab of the Investor Relations section of the
Navidea website at www.navidea.com.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a
biopharmaceutical company focused on the development of precision
immunodiagnostic agents and immunotherapeutics. Navidea is
developing multiple precision-targeted products based on its
ManoceptTM platform to enhance patient care by identifying the
sites and pathways of disease and enable better diagnostic
accuracy, clinical decision-making, and targeted treatment.
Navidea’s Manocept platform is predicated on the ability to
specifically target the CD206 mannose receptor expressed on
activated macrophages. The Manocept platform serves as the
molecular backbone of Tc 99m tilmanocept, the first product
developed and commercialized by Navidea based on the platform. The
development activities of the Manocept immunotherapeutic platform
are being conducted by Navidea in conjunction with its subsidiary,
Macrophage Therapeutics, Inc. Navidea’s strategy is to deliver
superior growth and shareholder return by bringing to market novel
products and advancing the Company’s pipeline through global
partnering and commercialization efforts.
For more information, please visit www.navidea.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170908005533/en/
Navidea Biopharmaceuticals, Inc.Jed Latkin, CFO/COO,
614-551-3416jlatkin@navidea.comorEdison AdvisorsTirth Patel,
646-653-7035tpatel@edisongroup.com
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2023 to Apr 2024